A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is comprised of a 4-week randomized, double-blind, placebo-controlled treatment period followed by an optional 8-week open-label extension (OLE) period.

This trial will evaluate the efficacy and safety of oral PRAX-114 flexibly dosed at 40 to 60 mg for 4 weeks compared to placebo in adults with PTSD. The OLE period consisting of treatment with 40 mg PRAX-114 for 8 weeks will provide additional efficacy and safety data.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Praxis Precision Medicines
• Treatments: Pramoxine

Criteria

Inclusion Criteria:

1. DSM-5 diagnosis of PTSD with duration >6 months, as confirmed by psychiatric evaluation.

2. CAPS-5 total score ≥30 at Screening and Baseline.

3. Body mass index (BMI) of 18 to 38 kg/m2.

Exclusion Criteria:

1. Experienced the index traumatic event before age 16.

2. Has an active legal, worker's compensation, or disability claim for PTSD.

3. Lifetime history of bipolar disorder, a psychotic disorder (eg, schizophrenia or schizoaffective disorder), or obsessive-compulsive disorder or a history of a psychotic mood episode in last 2 years.

4. HAM-D17 score of >18 at Screening or Baseline.

5. Any current psychiatric disorder (other than PTSD).

6. Lifetime history of seizures, including febrile seizures.

7. Daily consumption of more than 2 standard alcohol-containing beverages for males or more than 1 standard alcohol-containing beverages for females.